StockNews.com Downgrades Emergent BioSolutions (NYSE:EBS) to Hold

Emergent BioSolutions (NYSE:EBS) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday.

Several other analysts have also recently commented on EBS. Benchmark boosted their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Stock Up 6.1 %

EBS opened at $9.42 on Wednesday. The company has a market cap of $510.38 million, a PE ratio of -2.29 and a beta of 1.57. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a 50-day moving average price of $8.72 and a 200 day moving average price of $8.17. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EBS. BNP Paribas Financial Markets lifted its position in Emergent BioSolutions by 155.3% during the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock worth $414,000 after buying an additional 99,520 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after acquiring an additional 253,960 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after acquiring an additional 436,911 shares during the last quarter. Cetera Advisors LLC purchased a new stake in shares of Emergent BioSolutions in the first quarter valued at about $428,000. Finally, Headlands Technologies LLC acquired a new stake in Emergent BioSolutions during the second quarter worth about $969,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.